Related Experiment Video
Updated: May 5, 2026
Ferric Chloride-induced Murine Thrombosis Models
Published on: September 5, 2016
Cefazolin-induced coagulopathy: a case report
Olivier Zerbib1, Daniel Kovarsky2, Michael Oshrov3
1Depatement of General Intensive Care, Rabin Medical Center, Hasharon Hospital, Keren Kayemet Street, 49100, Petah Tikva, Israel. Zerbib.oliv@gmail.com.
Objective:
We report a case of cefazolin-induced coagulopathy, highlighting the importance of maintaining a high index of suspicion for this rare adverse effect of cefazolin.
Setting:
Department of intensive care, Rabin Medical Center, Hasharon Hospital, Petach Tikvah, Israel.
Patient:
A patient presented with shortness of breath, pleural effusion, iatrogenic pneumothorax, and bacteremia (positive for coagulase-negative staphylococcus).
Interventions:
Multiple thoracic drains and high-dose cefazolin therapy (2 gr intravenously three times per day).
Case Report:
A 78-year-old Caucasian woman with a history of mild renal dysfunction, chronic obstructive pulmonary disease, and morbid obesity was admitted to the Emergency Medicine Ward with new-onset shortness of breath. Initial evaluation revealed pleural effusion and positive blood cultures for Staphylococcus lugdunensis. Consequently, high-dose intravenous cefazolin (2 gr three times per day) was initiated. The patient's clinical condition deteriorated, necessitating mechanical ventilation and continuous renal replacement therapy in the intensive care unit. Management included echocardiography, placement of three pleural drains to address pneumothoraces, and intravenous antibiotic therapy. On the fourth day of cefazolin treatment, the patient experienced a significant rise in international normalized ratio (inr = 20 at day 4) levels, reaching 15-20, despite the absence of overt bleeding. After ruling-out primary hematologic disorders, cefazolin-induced coagulopathy was suspected. Cefazolin was discontinued, and vitamin K supplementation was promptly administered. This intervention led to a rapid normalization of international normalized ratio levels.
Conclusion:
Cefazolin-induced coagulopathy is a potentially life-threatening complication that may present with or without overt bleeding a few days after initiating intravenous cefazolin therapy. Owing to its rarity, this adverse effect requires heightened awareness and familiarity with predisposing risk factors to ensure timely recognition and management.
